Loading…
FitRX, LLC dba Zealthy was cited for unlawfully selling unapproved and misbranded compounded semaglutide drugs over the internet by making false or misleading claims that their products were equivalent to FDA-approved drugs like Wegovy and Ozempic. The company's website marketing materials violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by implying that compounded semaglutide was the same as FDA-approved versions and promoted it as a more cost-effective alternative when the products are not FDA-approved. The FDA determined these misleading claims regarding efficacy and equivalence resulted in the introduction of misbranded drugs into interstate commerce, which constitutes a prohibited act under the FDCA.